These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 662717)

  • 21. Enhancement of antitumor effectiveness of ICRF-159 (NSC-129943) against early L1210 leukemia by combination with cis-diamminedichloroplatinum (NSC-119875) or daunomycin (NSC-82151).
    Woodman RJ
    Cancer Chemother Rep 2; 1974 Mar; 4(1):45-52. PubMed ID: 4826499
    [No Abstract]   [Full Text] [Related]  

  • 22. Antitumour activity of some cyclophosphazenes.
    Labarre JF; Faucher JP; Levy G; Sournies F; Cros S; François G
    Eur J Cancer (1965); 1979 May; 15(5):637-43. PubMed ID: 510331
    [No Abstract]   [Full Text] [Related]  

  • 23. Combination chemotherapy: considerations for design and analysis.
    Lloyd HH
    Cancer Chemother Rep 2; 1974 Mar; 4(1):157-65. PubMed ID: 4826495
    [No Abstract]   [Full Text] [Related]  

  • 24. Antitumor activity of cis-dihalogenobis(1-phenyl-1,3-butanedionato)titanium (IV) compounds. A new class of antineoplastic agents.
    Keller HJ; Keppler B; Schmähl D
    J Cancer Res Clin Oncol; 1983; 105(1):109-10. PubMed ID: 6682104
    [No Abstract]   [Full Text] [Related]  

  • 25. [A new antitumor compound: hydroxy-9 ellipticin. Effect on mouse L 1210 leukemia].
    Le Pecq JB; Gosse C; Nguyen-Dat-Xuong ; Paoletti C
    C R Acad Hebd Seances Acad Sci D; 1973 Nov; 277(20):2289-91. PubMed ID: 4211276
    [No Abstract]   [Full Text] [Related]  

  • 26. [Action of nitrosoalkylureas and the longevity of tumor-bearing animals].
    Krutova TV; Kondradov AA; Ostrovskaia LA
    Izv Akad Nauk SSSR Biol; 1983; (6):843-50. PubMed ID: 6655115
    [No Abstract]   [Full Text] [Related]  

  • 27. [Experimental models for the treatment of acute myeloid leukemia].
    Burchenal JH
    Recenti Prog Med; 1975 Sep; 59(3):222-31. PubMed ID: 772768
    [No Abstract]   [Full Text] [Related]  

  • 28. Circadian optimization of the treatment of L1210 leukemia with 1-beta-D-arabinofuranosylcytosine, cyclophosphamide, vincristine and methylprednisolone.
    Burns ER; Scheving LE
    Chronobiologia; 1980; 7(1):41-51. PubMed ID: 7438892
    [No Abstract]   [Full Text] [Related]  

  • 29. Planning combined therapy--the interaction of experimental and clinical studies.
    Carter SK
    Cancer Chemother Rep 2; 1974 Mar; 4(1):3-11. PubMed ID: 4826498
    [No Abstract]   [Full Text] [Related]  

  • 30. Confidence interval about the response at the stationary point of a response surface, with an application to preclinical cancer therapy.
    Carter WH; Chinchilli VM; Campbell ED; Wampler GL
    Biometrics; 1984 Dec; 40(4):1125-30. PubMed ID: 6534413
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Drug-tumor sensitivity matching procedure using diffusion chambers in vivo.
    Cain BF; Calveley SB; Boreham BA; West C; Price NA; Walker DJ; Churchouse MJ
    Cancer Chemother Rep; 1974; 58(2):189-205. PubMed ID: 4857364
    [No Abstract]   [Full Text] [Related]  

  • 32. Antitumor activity of some acylhydrazines.
    Rutner H; Lewin N; Woodbury EC; McBride RJ; Rao KV
    Cancer Chemother Rep; 1974; 58(6):803-10. PubMed ID: 4447923
    [No Abstract]   [Full Text] [Related]  

  • 33. Chemotherapy research nurse.
    Hubbard S; Devita V
    Am J Nurs; 1976 Apr; 76(4):560-5. PubMed ID: 818899
    [No Abstract]   [Full Text] [Related]  

  • 34. Flavone acetic acid: a novel agent with preclinical antitumor activity against colon adenocarcinoma 38 in mice.
    Plowman J; Narayanan VL; Dykes D; Szarvasi E; Briet P; Yoder OC; Paull KD
    Cancer Treat Rep; 1986 May; 70(5):631-5. PubMed ID: 3708611
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Chemotherapy of advanced L1210 leukemia with platinum compounds in combination with other antitumor agents.
    Gale GR; Atkins LM; Meischen SJ; Smith AB; Walker EM
    Cancer Treat Rep; 1977; 61(3):445-50. PubMed ID: 872142
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Development of leukemia L-1210 after treatment with the methionine synthetase inhibitor quinoline dibromide].
    Kudriavtsev IA; Paramonova TD; Golenko OD; Miasishcheva NV
    Probl Gematol Pereliv Krovi; 1982 Jul; 27(7):27-31. PubMed ID: 7122454
    [No Abstract]   [Full Text] [Related]  

  • 37. Characteristics and response to certain cancer chemotherapeutic agents of an acute lymphocytic leukemia arising in a BALB-c times DBA-2F1 mouse.
    Yancey ST; Bleyer WA
    Cancer Res; 1974 Aug; 34(8):1866-9. PubMed ID: 4526157
    [No Abstract]   [Full Text] [Related]  

  • 38. [Research on substances with antiblastic activity. LXII. Synthesis and antineoplastic activity of pyrrolo-[2,1-b] quinazoline derivatives and of 4H-pyrrolo[2,1-b] [1,3] benzodiazepine derivatives].
    Massa S; De Martino G
    Farmaco Sci; 1978 Apr; 33(4):271-80. PubMed ID: 738446
    [No Abstract]   [Full Text] [Related]  

  • 39. Effects of 4,4'-diacetyl-diphenyl-urea-bis(guanylhydrazone) on leukemia L1210.
    Mihich E; Mulhern AI
    Cancer Res; 1968 Feb; 28(2):354-62. PubMed ID: 5641525
    [No Abstract]   [Full Text] [Related]  

  • 40. [Action of carminomycin on leukemic cell proliferation and some problems of its use in the combined therapy of leukemias].
    Egorov LV; Khanykova OK; Kuznetsova TV; Rudneva NA; Kozinets GI
    Antibiotiki; 1978 Sep; 23(9):833-6. PubMed ID: 697341
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.